Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were obs...
Guardado en:
Autores principales: | Kei Sonehara, Kazunari Tateishi, Taisuke Araki, Masamichi Komatsu, Jumpei Akahane, Hiroshi Yamamoto, Masayuki Hanaoka |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6c6b5dea8b844a03b042f08a23435fbf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neonatal adrenal insufficiency – beyond the common causes
por: Inês Pires Duro, et al.
Publicado: (2021) -
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi S, et al.
Publicado: (2020) -
A Single Episode of Hypoglycemia as a Possible Early Warning Sign of Adrenal Insufficiency
por: Tanaka S, et al.
Publicado: (2020) -
Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
por: Aya Yamashita, et al.
Publicado: (2021) -
Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
por: Anna E. Protasova, et al.
Publicado: (2021)